Clinical Data's Q4 Revenue Doubles as Net Loss Widens

Fourth-quarter R&D spending rose 140 percent to $12.8 million from $5.3 million for the same period in fiscal 2008. Clinical Data said that the increase was driven by Phase III confirmatory clinical and safety trials for vilazodone, the company's drug candidate for depression.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories